Olaparib

Generic Name
Olaparib
Brand Names
Lynparza
Drug Type
Small Molecule
Chemical Formula
C24H23FN4O3
CAS Number
763113-22-0
Unique Ingredient Identifier
WOH1JD9AR8
Background

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication

Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

First Posted Date
2024-11-13
Last Posted Date
2024-11-13
Lead Sponsor
Akeso
Target Recruit Count
150
Registration Number
NCT06686030

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

Phase 2
Not yet recruiting
Conditions
Ovarian Cancer Stage IV
Interventions
Drug: Olaparib
Drug: Bevacizumab
Drug: Durvalumab
First Posted Date
2024-10-21
Last Posted Date
2024-10-23
Lead Sponsor
British Columbia Cancer Agency
Target Recruit Count
40
Registration Number
NCT06650709

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

First Posted Date
2024-10-08
Last Posted Date
2024-12-18
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
30
Registration Number
NCT06630325
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

First Posted Date
2024-08-30
Last Posted Date
2024-08-30
Lead Sponsor
NRG Oncology
Target Recruit Count
880
Registration Number
NCT06580314

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

First Posted Date
2024-08-09
Last Posted Date
2024-12-12
Lead Sponsor
MOMA Therapeutics
Target Recruit Count
158
Registration Number
NCT06545942
Locations
🇺🇸

Investigative Site #104, Lake Mary, Florida, United States

🇺🇸

Investigative Site #110, Saint Louis, Missouri, United States

🇺🇸

Investigative Site #103, New York, New York, United States

and more 4 locations

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

First Posted Date
2024-07-29
Last Posted Date
2024-08-28
Lead Sponsor
Eisbach Bio GmbH
Target Recruit Count
144
Registration Number
NCT06525298
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase 2
Not yet recruiting
Conditions
Cholangiocarcinoma
Interventions
Drug: Durvalumab
Drug: Olaparib
First Posted Date
2024-06-04
Last Posted Date
2024-06-04
Lead Sponsor
Australasian Gastro-Intestinal Trials Group
Target Recruit Count
40
Registration Number
NCT06441747
Locations
🇦🇺

Royal Brisbane Women's Hospital, Brisbane, Queensland, Australia

🇦🇺

Flinders Medical Centre, Bedford Park, South Australia, Australia

🇦🇺

St John of God Hospital, Subiaco, Perth, Western Australia, Australia

and more 7 locations

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

First Posted Date
2024-05-17
Last Posted Date
2024-12-20
Lead Sponsor
University of Cologne
Target Recruit Count
29
Registration Number
NCT06419179
Locations
🇩🇪

University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

Phase 2
Recruiting
Conditions
Ovarian Cancer
Interventions
Drug: Bevacizumab
Drug: Olaparib
First Posted Date
2024-04-22
Last Posted Date
2024-05-09
Lead Sponsor
Vall d'Hebron Institute of Oncology
Target Recruit Count
100
Registration Number
NCT06377267
Locations
🇪🇸

Vall d'Hebron Institute of Oncology, Barcelona, Spain

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

First Posted Date
2024-04-09
Last Posted Date
2024-12-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
220
Registration Number
NCT06353386
Locations
🇨🇦

Centre Hospitalier de l'Université de Montréal ( Site 0200), Montréal, Quebec, Canada

🇵🇱

Uniwersyteckie Centrum Kliniczne ( Site 1405), Gdansk, Pomorskie, Poland

🇬🇧

Addenbrooke's Hospital ( Site 1902), Cambridge, Cambridgeshire, United Kingdom

and more 50 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy